ID   EB81-MEL.2
AC   CVCL_VU98
DR   Wikidata; Q93535594
RX   PubMed=14999777;
RX   PubMed=21216894;
CC   HLA typing: A*01:01,02:01; B*50,57; C*06 (PubMed=14999777).
CC   Derived from site: Metastatic; Inguinal lymph node; UBERON=UBERON_0001542.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_VU97 ! EB81-MEL
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 5
//
RX   PubMed=14999777; DOI=10.1002/ijc.20038;
RA   Ma W.-B., Germeau C., Vigneron N., Maernoudt A.-S., Morel S., Boon T.,
RA   Coulie P.G., van den Eynde B.J.;
RT   "Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and
RT   presented to cytolytic T lymphocytes by HLA-A2.";
RL   Int. J. Cancer 109:698-702(2004).
//
RX   PubMed=21216894; DOI=10.1158/0008-5472.CAN-10-2693;
RA   Corbiere V., Chapiro J., Stroobant V., Ma W.-B., Lurquin C., Lethe B.,
RA   van Baren N., van den Eynde B.J., Boon T., Coulie P.G.;
RT   "Antigen spreading contributes to MAGE vaccination-induced regression
RT   of melanoma metastases.";
RL   Cancer Res. 71:1253-1262(2011).
//